TENAX THERAPEUTICS, INC.: 10-K filed 2018-04-02
What TENAX THERAPEUTICS, INC. reported in its annual report filed 2018-04-02 (fiscal FY 2017): 30 published measures, 62 facts as tagged in accession 0001654954-18-003517.
This filing
- Form
- 10-K (annual report)
- Filed
- 2018-04-02
- Fiscal period
- fiscal FY 2017
- Accession
- 0001654954-18-003517 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All TENAX THERAPEUTICS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 9,890,701 | USD | |
| At 2016-12-31 | 23,340,175 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 1,008,840 | USD | |
| At 2016-12-31 | 6,199,237 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 8,881,861 | USD | |
| At 2016-12-31 | 17,140,938 | USD | |
| At 2015-12-31 | 60,423,348 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 1,604,810 | USD | |
| At 2016-12-31 | 9,995,955 | USD | |
| At 2015-12-31 | 3,660,453 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-12-31 | -8,839,682 | USD | 365 |
| 2016-01-01 to 2016-12-31 | -43,923,904 | USD | 366 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-12-31 | -12,140,517 | USD | 365 |
| 2016-01-01 to 2016-12-31 | -15,871,300 | USD | 366 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-12-31 | 4,537 | USD | 365 |
| 2016-01-01 to 2016-12-31 | 2,884 | USD | 366 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-12-31 | 3,749,372 | USD | 365 |
| 2016-01-01 to 2016-12-31 | 22,206,802 | USD | 366 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | -213,499,285 | USD | |
| At 2016-12-31 | -204,659,603 | USD |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-12-31 | 0 | USD | 365 |
| 2016-01-01 to 2016-12-31 | -7,962,100 | USD | 366 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 9,945 | USD | |
| At 2016-12-31 | 19,105 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-12-31 | 79,589 | USD | 365 |
| 2016-01-01 to 2016-12-31 | 1,062 | USD | 366 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-12-31 | -9,205,898 | USD | 365 |
| 2016-01-01 to 2016-12-31 | -52,650,739 | USD | 366 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 8,062,893 | USD | |
| At 2016-12-31 | 13,628,175 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 1,008,840 | USD | |
| At 2016-12-31 | 6,199,237 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 611,861 | USD | |
| At 2016-12-31 | 727,599 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 50,171 | USD | |
| At 2016-12-31 | 72,599 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-12-31 | 9,205,898 | USD | 365 |
| 2016-01-01 to 2016-12-31 | 52,650,739 | USD | 366 |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-12-31 | 5,678,581 | USD | 365 |
| 2016-01-01 to 2016-12-31 | 6,245,958 | USD | 366 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-12-31 | 3,527,317 | USD | 365 |
| 2016-01-01 to 2016-12-31 | 13,139,681 | USD | 366 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 1,411,840 | shares | |
| At 2016-12-31 | 1,406,002 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | -16,193 | USD | |
| At 2016-12-31 | -18,718 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 574,051 | USD | |
| At 2016-12-31 | 586,730 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 564,106 | USD | |
| At 2016-12-31 | 567,625 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 8,435 | USD | |
| At 2016-12-31 | 1,106,785 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 363,306 | USD | |
| At 2016-12-31 | 5,245,546 | USD |
Net deferred tax assets
Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 41,325 | USD | |
| At 2016-12-31 | 56,180 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-12-31 | 8,837,157 | USD | 365 |
| 2016-01-01 to 2016-12-31 | 43,813,180 | USD | 366 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-12-31 | 13,621 | USD | 365 |
| 2016-01-01 to 2016-12-31 | 18,952 | USD | 366 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-12-31 | 366,216 | USD | 365 |
| 2016-01-01 to 2016-12-31 | 764,735 | USD | 366 |
Inspect the source
- Entity
- TENAX THERAPEUTICS, INC. / CIK 0000034956
- Captured
- 2026-09-19T14:46:45.117Z
- SEC response SHA-256
3f4f90f5f823d316ffb20bc63506ae090888657f5ff1cb9568439e153f028cf5
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000034956.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))